16089 Safety of ATI-502, a novel topical JAK1/3 inhibitor, in adults with moderate to severe atopic dermatitis: Results from a phase 2a open-label trial

Background: AD has responded to treatment with oral and topical JAK inhibitors. Safety of ATI-502 Topical Solution was evaluated in subjects with moderate to severe AD.